US-EU deal winners and losers

The US and EU have established a framework for a major trade deal, introducing a 15% US tariff on many EU goods while reducing EU tariffs on US cars to 2.5%. This agreement, which aims to provide market certainty and deepen US-EU energy ties with a commitment for $750 billion in EU purchases of US energy, is expected to benefit US energy and aviation sectors. However, it raises concerns about increased costs for US consumers and highlights internal EU divisions, with significant financial implications for sectors like German automotive and EU pharmaceuticals.

Analysis

A new US-EU trade framework has been established, characterized by a general 15% US tariff on European goods, which has elicited a mixed response across markets and sectors. While Asian and European equities initially rose on the news, driven by a preference for certainty over continued ambiguity, the underlying economics present significant headwinds. Capital Economics projects a potential 0.5% negative impact on EU GDP, and US consumers are expected to face higher costs. The US energy sector emerges as a clear beneficiary, with the EU committing to $750 billion in purchases of US LNG, oil, and nuclear fuels to displace Russian sources. Similarly, the transatlantic aviation industry benefits from a zero-tariff arrangement on aircraft and parts. Conversely, key European industries face substantial pressure; German automakers will absorb a 15% tariff, a rate the VDA trade body warns will cost the industry billions annually. The EU pharmaceutical sector also faces disappointment and uncertainty with the imposition of new tariffs where an exemption was anticipated. The agreement exposes significant geopolitical fissures within the EU, with vocal opposition from French and Hungarian leadership, posing a risk to the deal's final ratification by all 27 member states.

Key Decisions for Investors

• Consider overweighting US energy producers, particularly LNG exporters, and the transatlantic aviation supply chain, which are positioned as direct beneficiaries of the agreement's specific purchase and zero-tariff clauses.
• Exercise caution with European automotive stocks, as the new 15% US tariff structure is poised to directly compress margins and profitability for major German manufacturers.
• Monitor the EU pharmaceutical sector for clarity on tariff specifics, as the current uncertainty and imposition of new duties represent a significant headwind for companies with high US market exposure.
• While the deal provided an initial market lift, investors should track the EU ratification process closely, as political divisions flagged by French and Hungarian officials could introduce significant volatility and undermine the framework's stability.
• Evaluate US automakers' positions carefully, as they face a complex competitive landscape where lower EU tariffs on their exports are offset by potentially being undercut domestically by European imports subject to a lower tariff than US cars assembled abroad.